Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

NCT05118958 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema

Interventions

DRUG: KVD824 Prototype 1 modified-release tablet
DRUG: KVD824 Prototype 2 modified-release tablet
DRUG: KVD824 Immediate-Release Capsule
DRUG: Placebo to KVD824 Prototype 1
DRUG: KVD824 Prototype 3 modified-release tablet

Sponsor

KalVista Pharmaceuticals, Ltd.